Back to News
Market Impact: 0.28
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Source: 247wallst.com
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Moderna shares surged Monday after its Phase 3 adjuvant melanoma study of intismeran autogene was selected for a Presidential Symposium presentation. The selection highlights visibility for Moderna's investigational individualized mRNA neoantigen therapy, though the article provides no clinical-efficacy data or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
MRNA0.72
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- While biotech bets swing on trial data, this dividend payer gained 72% since 2024
- RIP the Cybertruck: Elon Musk says Tesla will wind down production of its most polarizing EV
- Tesla will stop making the Cybertruck in 2027
- Tesla is 'winding down' Cybertruck production at its Texas Gigafactory
- Small retailers brace for 'huge hit' this holiday season as shipping costs spike